Abstract: Disclosed herein are methods of treatment for an intraocular pressure (IOP)-associated condition in a subject, that include administering to the subject an effective amount of a tissue plasminogen activator (tPA) therapeutic agent. In one embodiment, the IOP-associated condition is glaucoma. The administration of a tPA therapeutic agent can be an extended administration intended to cause a reduction in IOP in the subject for a period of at least one day to a year or more, relative to IOP levels in the subject prior to administration of the tPA therapeutic agent. The tPA therapeutic agent can be, for example, tPA, a tPA derivative, a small molecule direct or indirect tPA agonist, or a gene therapy vector.

Abstract: Described herein dog and cat food additives and compositions comprising secretory IgA.

Abstract: The present invention relates to a composition comprising the mixed extract of mulberry and Poria cocos peel for preventing, improving or treating neurodegenerative disorders. The mixed extract of mulberry and Poria cocos peel which is the active ingredients contained in the composition of the present invention, has a memory improving activity through inhibiting of acetylcholine esterase and a neuroprotective effects and neuron protection by inhibiting the formation of beta amyloid and tau phosphorylation and promoting NGF production. Thus, the present invention may be useful as a pharmaceutical composition for preventing or treating degenerative neurological diseases, or as a health food for the above purpose.

Abstract: A diagnostic system for measuring and analyzing startle response of a subject comprises a stimuli delivery module, whereby startle stimuli and prepulse stimuli are delivered to subject; said diagnostic system comprises at least one sensor module, whereby the startle response of subject are detected and recorded; said sensor module comprises at least one electrode and one eyeblink response measuring means; and said diagnostic system comprises a diagnosis module whereby the features of the startle response and prepulse inhibition of subject are extracted and analyzed.

Abstract: Anti-microbial monoclonal antibodies and variant antibodies having a heavy chain constant regions with at least one amino acid substitution are provided. Such antibodies may be used to prevent or treat microbial infections.

Abstract: Provided are compositions and methods for treating a condition or disorder mediated by fascin activity in a subject in need thereof which method comprises administering to the subject a therapeutically effective amount of at least one compound of any one of Formula I-a to I-n, II, II-a, II-b or III or a pharmaceutically acceptable salt thereof.

Abstract: The present invention is directed to a peptide, multimer, conjugate, analog, derivative or mimetic thereof that inhibits the activity of VISTA. The invention further contemplates therapeutic use of the VISTA antagonist peptide, multimer, conjugate, derivative or mimetic thereof, including treating or preventing cancer, bacterial infections, viral infections, parasitic infections and fungal infections, as well as research uses of the antagonist.

Abstract: The method of treating a bacterial infection using colostrum includes administering an effective amount of colostrum to a subject in need thereof. The infection can be caused by G+ or G? bacteria. The colostrum administered may be selected from the group consisting of bovine colostrum, camel colostrum, and a mixture of bovine colostrum and camel colostrum. The bacterial infection may be selected from the group consisting of Staphylococcus aureus subs. aureus Rosenbach, Escherichia coli, Pseudomonas aeruginosa, and Methicillin-resistant Staphylococcus aureus. A colostrum composition can include a mixture of bone and camel colostrum and a pharmaceutically acceptable carrier.

Abstract: A minimal antigen delivery system consists essentially of PEGylated stealth liposomes loaded with an immunogenic human leukocyte antigen (HLA) class restricted peptide and surface modified with a cell targeting peptide which mediates binding and internalization of the liposomes into a target cell.

Abstract: An immunomodulator for use in the treatment, reduction, inhibition or control of a neoplastic disease in a patient intended to undergo checkpoint inhibition therapy, simultaneously, separately or sequentially with administration of the immunomodulator. The immunomodulator preferably comprises a whole cell Mycobacterium, for example, M. vaccae or M. obuense.

Abstract: Disclosed are antimicrobial peptides capable of inhibiting and killing multiple drug-resistant bacteria, including XH-12C, XH-12B and XH-12A. The application further provides uses of the antimicrobial peptides in the preparation of a drug for inhibiting and/or killing fungi, Gram-positive bacteria, Gram-negative bacteria and drug-resistant bacteria and in the manufacture of medical carriers.

Abstract: The present invention provides a pharmaceutical formulation comprising an anti-epidermal growth factor receptor (EGFR) antibody. The pharmaceutical formulation has low turbidity, without showing aggregation or particle formation, even under accelerated conditions, and exhibits good stability. Therefore, the pharmaceutical formulation can be effectively used for the treatment of disorders such as cancer.

Abstract: Disclosed are domain antibodies that monovalently bind CD28. Domain antibodies that are monovalent for binding of CD28 can inhibit CD28 activity. In one aspect, a domain antibody consists of or comprises a single immunoglobulin variable domain that specifically binds and antagonizes the activity of CD28, in an aspect, without substantially agonizing CD28 activity. In another aspect, the domain antibody is a human domain antibody. The disclosure further encompasses methods of antagonizing CD80 and/or CD86 interactions with CD28 in an individual and methods of treating diseases or disorders involving CD80 and/or CD86 interactions with CD28, the methods involving administering a domain antibody to the individual.

Abstract: Methods for the treatment of CD30-expressing cancers are provided. The methods comprise administering to a subject in need thereof a weekly dose of from about 0.8 mg/kg to about 1.8 mg/kg of an antibody-drug conjugate compound having formula (I); or a pharmaceutically acceptable salt thereof; wherein: mAb is an anti-CD30 antibody unit, S is a sulfur atom of the antibody, A- is a Stretcher unit, and p is from about 3 to about 5.

Abstract: The present invention provides antagonists and methods of use thereof in the treatment of cancer and abnormal immune suppression diseases.

Abstract: Oligodeoxynucleotide-based immunostimulatory Toll-Like Receptor 9 (TLR9) agonists are described. Also described are compositions comprising the TLR9 agonists, methods of making the TLR9 agonists, and methods of using the TLR9 agonists to treat immune diseases, disorders or conditions, such as viral infections or cancer.

Abstract: The invention relates to a method of identifying molecules which inhibit the virulence machinery of Pseudomonas aeruginosa, to a device for identifying a molecule which inhibits the virulence machinery of Pseudomonas aeruginosa, to novel compounds which inhibit the virulence machinery of Pseudomonas aeruginosa, to compounds for use for preventing and/or treating a pathogenic infection caused by Pseudomonas aeruginosa and also to pharmaceutical compositions for preventing and/or treating a pathogenic infection caused by Pseudomonas aeruginosa.

Abstract: The present invention provides a method for producing an antibody against podocalyxin expressed specifically in cancer cells. The method includes a step of introducing a nucleic acid encoding all or a portion of podocalyxin into cells expressing a cancer cell-specific sugar chain structure to cause cancer cell-specific podocalyxin or a portion thereof to be expressed therein, a step of immunizing a non-human mammal with the cancer cell-specific podocalyxin or portion thereof to obtain antibodies, and a step of purifying the antibodies by primary screening using purified cancer cell-specific podocalyxin or a portion thereof.

Abstract: Fully human monoclonal Abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for IL-1? and (ii) a constant region that is effective at both activating the complement system though C1q binding and binding to several different Fc receptors.

Abstract: Disclosed are antimicrobial peptides capable of inhibiting and killing multiple drug-resistant bacteria, including XH-12C, XH-12B and XH-12A. The application further provides uses of the antimicrobial peptides in the preparation of a drug for inhibiting and/or killing fungi, Gram-positive bacteria, Gram-negative bacteria and drug-resistant bacteria and in the manufacture of medical carriers.

Abstract: Herein is reported a heterodimeric polypeptide comprising a first polypeptide comprising in N-terminal to C-terminal direction at least a portion of an immunoglobulin hinge region, which comprises one or more cysteine residues, an immunoglobulin CH2-domain and an immunoglobulin CH3-domain, and a second polypeptide comprising in N-terminal to C-terminal direction at least a portion of an immunoglobulin hinge region, which comprises one or more cysteine residues, an immunoglobulin CH2-domain and an immunoglobulin CH3-domain, wherein the first polypeptide comprises the mutations Y349C, T366S, L368A and Y407V (hole-chain) and the second polypeptide comprises the mutations S354C and T366W (knob-chain), and wherein the first polypeptide (hole-chain) comprises the mutations i) I253A or I253G, and ii) L314A or L314G or L314D, and wherein the first polypeptide and the second polypeptide are connected by one or more disulfide bridges, and wherein the CH3-domain of the first polypeptide and the CH3-domain of the second

Abstract: In one aspect, the invention relates to a composition including a first polypeptide having the sequence set forth in SEQ ID NO: 1 and a second polypeptide having the sequence set forth in SEQ ID NO: 2. In one embodiment, the composition includes about 120 ?g/ml of a first polypeptide including the amino acid sequence set forth in SEQ ID NO: 1, 120 ?g/ml of a second polypeptide including the amino acid sequence set forth in SEQ ID NO: 2, about 2.8 molar ratio polysorbate-80 to the first polypeptide, about 2.8 molar ratio polysorbate-80 to the second polypeptide, about 0.5 mg/ml aluminum, about 10 mM histidine, and about 150 mM sodium chloride. In one embodiment, a dose of the composition is about 0.5 ml in total volume. In one embodiment, two-doses of the composition induce a bactericidal titer against diverse heterologous subfamily A and subfamily B strains in a human.

Abstract: This invention concerns anti-inflammatory agents, compositions, and methods for treating inflammatory disorders.

Abstract: The present description relates to an anti-S1008 protein for treating leukemia. More specifically, is disclosed anti-S100A8 antibody that specifically binds to a portion of S100A8 protein and/or a S100A8/S100A9 heterodimer for treating leukemia.

Abstract: The invention relates to an antibody, a fragment or a derivative thereof, for use as an antiretroviral drug targeting a virus belonging to human endogenous retroviruses type W (HERV-W), wherein said antibody, fragment or derivative thereof is directed against HERV-W Envelope protein (HERV-W Env). The invention also relates to a composition comprising said antibody and a retroviral reverse-transcriptase inhibitory drug, for use as an antiretroviral drug targeting a virus belonging to HERV-W.

Abstract: The invention provides stabilized aqueous pharmaceutical etanercept compositions suitable for long-term storage of etanercept, methods of manufacture of these compositions, methods of administration, and kits containing same.

Abstract: Provided are peptides suitable for early detection of active M. tuberculosis (Mtb) infection in immunocompromised individuals. The peptides can form complexes with antibodies directed to Mtb antigens MS, MPT51, ESAT6 or CFPIO. Also provided are methods for detected of complexes of the peptides and the antibodies. The presence of complexes aids in predicting risk in immunocompromised individuals of developing active tuberculosis.

Abstract: The present invention provides antagonists and methods of use thereof in the treatment of cancer and abnormal immune suppression diseases.

Abstract: There is provided methods of determining tuberculosis (TB) infection status in an individual comprising: (i) providing a sample comprising T-cells; (ii) exposing the sample of (i) to one or more TB antigens; (iii) identifying T-cells in the sample that are CD4 positive and (a) secrete TNF-? without secreting IFN-?; or (b) secrete IFN-? without secreting TNF-?; (iv) identifying those cells of (iii) which are also CCR7 and, CD127 negative; and optionally (v) calculating the cells identified in (iv) as a percentage of those identified in (iii); wherein the identification of cells in (iv) and/or the percentage of T-cells calculated in (v) correlates to TB infection status of the individual, and wherein steps (iii) and (iv) can be carried out either sequentially or simultaneously. There are also provided compositions and kits for use in such methods.

Abstract: An isolated or recombinant CD83 binding protein may include an antigen binding domain, wherein the antigen binding domain binds specifically to CD83 or a cell expressing CD83.

Abstract: In a first aspect, the present invention relates to a recombinant polypeptide containing a domain comprising at least two antibody units whereby the first antibody unit is an anti-CD30 single chain antibody unit while the second antibody unit is a antibody unit being specific for an antigen present on the surface of a predetermined target cell. In particular, the present invention relates to a recombinant polypeptide containing at least the following domains starting from the N-terminus to the C-terminus: a first domain containing an anti-CD30 single chain antibody unit, in particular, HRS3 scFv of SEQ ID No. 2 or homologs thereof having at least 70% identity with SEQ ID No. 2 binding specifically to CD30, and an antibody unit said antibody unit being specific for an antigen present on the surface of a predetermined target cell, in particular, being specific for a tumor-associated antigen; optionally a spacer domain; a trans-membrane domain; and a cytoplasmatic signalling domain.

Abstract: Methods and apparatuses for monitoring the state of health of dairy cows, in particular of entire dairy herds are provided. The method is based on analysing the haptoglobin (HP) biomarker and part of the polymeric immunoglobulin receptor (PIGR), the secretory component (SC), in a milk sample. This allows diagnosis of mastitis or systemic diseases which occur outside the udder on the basis of the protein biomarker described here. This further allows regular monitoring of the general state of health of a dairy herd. Diagnostic methods, apparatuses, and diagnostic kits for carrying out these methods are included.

Abstract: The present invention provides an antibody or a functional fragment thereof that specifically binds to Proprotein convertase subtilisin/kexin type 9 (PCSK9) with high affinity, also provides a nucleic acid molecule encoding the antibody of the invention or the functional fragment thereof, for expressing an expression vector and a host cell of the antibody or the functional fragment thereof, and also provides a method for producing the antibody or the functional fragment thereof. The present invention provides that the antibody or the functional fragment thereof is used for treating diseases such as dyslipidemia.

Abstract: The present invention relates to the seminal discovery that P-selectin glycoprotein ligand-1 (PSGL-1) modulates the immune system and immune responses. Specifically, the present invention provides PSGL-1 agonists and antagonists which increase the survival of multifunctional T cells and viral clearance. The present invention further provides methods of treating infectious diseases, cancer and immune and inflammatory diseases and disorders using a PSGL-1 modulator.

Abstract: The invention described herein comprises compounds and a method of treating cancer comprising administering to a subject having cancer one of the compounds in conjunction with another therapeutic treatment of cancer. The compounds inhibit signaling by a member of the TGF-? superfamily such as Nodal or Activin.

Abstract: A method of treating a medical disorder associated with the presence of pathogenic B cells expressing B cell maturation antigen (BCMA), the method comprising administering to a subject an isolated antibody or antibody fragment comprising specific VH and VL domain complementary determining region (CDR) sequences, wherein the antibody or fragment thereof specifically binds an epitope of the extracellular domain of CD269 (BCMA).

Abstract: This invention concerns anti-inflammatory agents, compositions, and methods for treating inflammatory disorders.

Abstract: The present invention provides a method for the treatment of a patient comprising administering to the patient an initial dose of between about 1 mg and about 150 mg of a MAdCAM antagonist antibody. Biomarkers for assessing a patient's response to anti-MAdCAM treatment are also provided.

Abstract: The invention provides antibodies against the antigen containing the Dsg2 extracellular domain 2. Also provided is the method of using the antibodies in treatment or prevention of a cancer.

Abstract: The present disclosure provides binding-triggered transcriptional switch polypeptides, nucleic acids comprising nucleotide sequences encoding the binding-triggered transcriptional switch polypeptides, and host cells genetically modified with the nucleic acids. The present disclosure also provides chimeric Notch receptor polypeptides, nucleic acids comprising nucleotide sequences encoding the chimeric Notch receptor polypeptides, and host cells transduced and/or genetically modified with the nucleic acids. The present disclosure provides transgenic organisms comprising a nucleic acid encoding a binding triggered transcriptional switch polypeptide and/or a chimeric Notch receptor polypeptide of the present disclosure. Binding triggered transcriptional switch polypeptides and chimeric Notch receptor polypeptides of the present disclosure are useful in a variety of applications, which are also provided.

Abstract: The present disclosure provides binding-triggered transcriptional switch polypeptides, nucleic acids comprising nucleotide sequences encoding the binding-triggered transcriptional switch polypeptides, and host cells genetically modified with the nucleic acids. The present disclosure also provides chimeric Notch receptor polypeptides, nucleic acids comprising nucleotide sequences encoding the chimeric Notch receptor polypeptides, and host cells transduced and/or genetically modified with the nucleic acids. The present disclosure provides transgenic organisms comprising a nucleic acid encoding a binding triggered transcriptional switch polypeptide and/or a chimeric Notch receptor polypeptide of the present disclosure. Binding triggered transcriptional switch polypeptides and chimeric Notch receptor polypeptides of the present disclosure are useful in a variety of applications, which are also provided.

Abstract: The present invention is directed generally to dry cell culture media or feeds in pellet formats which can be reconstituted into liquid media for culturing cells in vitro. Each pellet composition may comprise the same or a different composition; for example, different vitamins, amino acids, buffers, trace salts, pH, iron chelators, etc. The invention also relates to methods of making dry cell culture media by altering ratios of different pellet compositions, or, methods of making modular dry cell culture media, or customizing media formulations for growing a cell type using pellets. According to the invention, media pellets may be easier to handle either before reconstitution, during shipping and handling; and/or during reconstitution. Media pellets may be used in any container like bags including sterile, single use bags for preparing media formulations. The invention also relates to kits and culture systems using media pellets.

Abstract: Methods of reducing cytokine levels and methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) are provided. Such methods include, but are not limited to, methods of treating inflammatory conditions, such as rheumatoid arthritis.

Abstract: Disclosed herein are switchable chimeric receptors, switchable chimeric receptor effector cells and chimeric receptor effector cell switches. The switchable chimeric receptor-ECs are generally T cells. The chimeric receptors have non-antibody extracellular domains that recognize a chimeric receptor binding partner on the chimeric receptor-EC switch or target cell. The chimeric receptor-ECs and switches may be used for the treatment of a disease or condition in a subject in need thereof.

Abstract: The invention relates to methods of treating cancer in a subject, comprising administering to the subject a therapeutically effective amount of an inhibitor of the interaction between the PD-1 receptor and its ligand PD-L1.

Abstract: Described herein are methods comprising administering to a mammalian subject an effective amount of an annexin chimeric fusion protein, wherein the annexin chimeric fusion protein comprises at least one immunogenic antigen, thereby enhancing the antigen specific immune response relative to administration of the immunogenic antige alone. Methods and kits for treating or preventing recurrence of hyper proliferating diseases, e.g., cancer, are described. A method may comprise priming a mammal by administering to the mammal an effective amount of a chemotherapeutic agent and boosting the mammal by administering to the mammal an effective amount of an annexin chimeric fusion.

Abstract: The present invention relates to methods of treatment of acute myeloid leukemia with anti-CD38 antibodies.

Abstract: A stable anti-PD-1 antibody pharmaceutical preparation and an application thereof in a medicine. The anti-PD-1 antibody pharmaceutical preparation comprises an anti-PD-1 antibody, a buffer, and can further comprise at least one type of stabilizer, and optionally can further comprise a surfactant. The anti-PD-1 antibody pharmaceutical preparation of the present invention can effectively suppress antibody aggregation and deamidation, thereby preventing degradation of an antibody product, resulting in a stable injectable pharmaceutical preparation.

Abstract: A method for preventing, improving, or treating fatty liver includes administering an effective amount of an azelaic acid or a pharmaceutically acceptable salt thereof to a subject. Azelaic acid which is a compound primarily contained in a natural product, has no or fewer side effects and reduces accumulation of triglycerides in liver tissue, and thus may prevent, improve, or treat a non-alcoholic fatty liver. In addition, due to an anti-inflammatory effect, azelaic acid may be used in the treatment of steatohepatitis. Therefore, the azelaic acid according to the present disclosure is expected to be effectively used in a food composition, a pharmaceutical composition and a health functional food composition to treat fatty liver or steatohepatitis.

Abstract: In alternative embodiments, the invention provides vaccines, pharmaceutical compounds and formulations for diagnosing, preventing, treating or ameliorating Group A Streptococcus (GAS), Group C Streptococcus (GCS), or Group A Streptococcus (GGS), infections, or other pathogenic Streptococcus infections. In alternative embodiments, the invention provides compositions such as diagnostic tests, assays, immunoassays and test strips, and methods, for detecting or diagnosing the presence of a Streptococcal infection, e.g., Group A Streptococcus (GAS), Group C Streptococcus (GCS), or Group A Streptococcus (GGS), infections, or other pathogenic Streptococcus infections.